DE:5IU Stock Latest News
Company AnnouncementsIsofol Sets AGM 2027 Nomination Committee as Cancer Drug Development Advances4d ago
Company AnnouncementsIsofol schedules investor updates to showcase new data on cancer drug arfolitixorin2w ago
Company AnnouncementsIsofol to Highlight Cancer Drug Candidate at BioStock Investor Meetings1M ago
Company AnnouncementsIsofol Deepens Arfolitixorin Push as Cash Reserves Bolster Pre-Revenue Pipeline2M ago
Company AnnouncementsIsofol expands arfolitixorin cancer trial to accelerate patient recruitment2M ago
Company AnnouncementsIsofol advances arfolitixorin trial with final dose cohort in colorectal cancer study3M agoCompany AnnouncementsIsofol Medical AGM Backs New Incentive Schemes and Withholds 2025 Dividend5M ago
Company AnnouncementsIsofol strengthens finances and advances arfolitixorin trial in first quarter5M ago
Company AnnouncementsIsofol Expands Share Capital After Warrant Exercise6M ago
Company AnnouncementsIsofol Medical Calls 2026 Annual General Meeting in Gothenburg6M ago- Company AnnouncementsIsofol Wins Regulatory Nod to Broaden and Speed Up Key Arfolitixorin Trial6M ago
Company AnnouncementsIsofol publishes 2025 reports as arfolitixorin program shows progress6M ago
Company AnnouncementsIsofol Raises 18.9 MSEK via TO1 Warrant Exercise and Directed Share Issue7M agoCompany AnnouncementsIsofol Extends Arfolitixorin Rights Into Autism While Keeping Cancer Focus7M ago
Company AnnouncementsIsofol Sets TO1 Warrant Price and Exercise Window, Targets SEK 19 Million Raise7M ago
- Company AnnouncementsIsofol Secures Stakeholder Support Covering 42% of Upcoming TO1 Warrant Exercise7M ago
- Company AnnouncementsIsofol to Add Major Shareholder Christian Haglund to Expanded Board7M ago
- Company AnnouncementsIsofol to Showcase Cancer Drug Candidate at Key March Investor Events8M ago
- Company AnnouncementsIsofol Reports Strong Early Data for Arfolitixorin in Difficult-to-Treat Colorectal Cancer8M ago
Company AnnouncementsIsofol strengthens arfolitixorin program with new EU patent and advancing trials8M agoCompany AnnouncementsIsofol Showcases Arfolitixorin Trial Design at ASCO GI as Phase Ib/II Study Advances9M ago